Jcr pharmaceuticals selected for japan's regenerative medicine cdmo subsidy program

Hyogo, japan--(business wire)--jcr pharmaceuticals co., ltd. (tse 4552; “jcr”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, has been selected for the ministry of economy, trade and industry's “regenerative cdmo subsidy” as of july 15, 2025. the subsidy will support facility upgrades and equipment installation to expand biomanufacturing capacity for regenerative, cell, and gene therapies. project overview 1) project title jcr rege.
CDMO Ratings Summary
CDMO Quant Ranking